The SS-31 half-life is about two hours in human plasma, which is why elamipretide is dosed daily or by infusion. See the PK data, dosing, and safety facts.
The SS-31 half-life is roughly two hours in human plasma after a subcutaneous injection, with peak concentrations appearing 30 to 60 minutes after the dose. Elamipretide, the clinical name for SS-31, leaves the bloodstream quickly, which is why studies rely on once-daily injections or continuous infusions rather than occasional dosing.
What SS-31 (Elamipretide) Is
SS-31 is a synthetic tetrapeptide designed to concentrate inside mitochondria. It also appears in the literature as elamipretide, MTP-131, and Bendavia, depending on the research program.
Rather than binding a receptor, SS-31 attaches to cardiolipin on the inner mitochondrial membrane. That detail matters for half-life discussions, because the peptide's activity depends more on where it accumulates than on how long it lingers in circulation.
Research interest centers on mitochondrial dysfunction, heart failure, skeletal muscle performance, and rare genetic conditions such as Barth syndrome. In every one of those settings, pharmacokinetics set the dosing schedule.
SS-31 Half-Life Numbers at a Glance
Pharmacokinetic data from human and animal studies paint a consistent picture: fast absorption, fast plasma clearance, and a longer-lasting footprint in tissue.
| Parameter | Typical reported value | What it means |
|---|---|---|
| Plasma half-life | About 1.5 to 2.5 hours | Most of a dose leaves the bloodstream within roughly half a day |
| Peak levels, subcutaneous | 30 to 60 minutes | Rapid absorption from the injection site |
| Peak levels, IV infusion | End of the infusion | The route used in earlier cardiac studies |
| Steady state | About 2 to 3 days of daily dosing | Levels stabilize quickly because clearance is fast |
| Breakdown | Peptidase metabolism | Not primarily dependent on liver enzymes |
| Tissue residence | Longer than plasma half-life | Mitochondrial binding may extend the effect |
These figures come from small trials and animal models, so treat them as ranges rather than fixed constants. Body weight, kidney function, and injection technique can all shift exposure.
Timing has practical consequences. A dose given at night peaks while you sleep, while an injection given before training peaks during the session. Neither pattern has been formally compared in controlled trials.
Why a Two-Hour Half-Life Shapes Dosing
After about five half-lives, roughly 10 hours, most of an SS-31 dose has left the bloodstream. Even so, the largest human trials used a single 40 mg subcutaneous injection per day.
That gap between plasma exposure and dosing frequency sits at the center of ss-31 peptide dosing. Investigators assume the peptide keeps working after blood levels fall because it remains bound inside mitochondria.
| Regimen | Typical protocol | Where it appears |
|---|---|---|
| Subcutaneous, once daily | 40 mg per day | Phase 2 and Phase 3 elamipretide trials |
| Weight-based subcutaneous | About 0.1 to 1 mg/kg per day | Smaller human studies |
| Intravenous infusion | 0.05 to 0.5 mg/kg per hour | Early heart failure trials |
| Twice-daily or split dosing | Divided doses | Exploratory research settings |
Split dosing exists mainly to smooth out the peaks and troughs created by such fast clearance. None of these protocols represents an approved human dose.
Does the Short Half-Life Limit SS-31's Effects?
Probably less than the raw number suggests. SS-31 is taken up by mitochondria-rich tissues such as heart, skeletal muscle, kidney, and brain, and it can stay associated with cardiolipin far longer than it stays in plasma.
Animal studies show mitochondrial effects that outlast plasma exposure by a wide margin. Human data are thinner, and no large trial has directly linked plasma half-life to clinical outcomes.
Some protocols combine compounds that act through different pathways. Research using ss-31 and mots-c together rests on the idea that a mitochondria-targeted peptide and a mitochondrial-derived peptide may complement each other, though human combination data remain limited.
People assembling multi-peptide schedules often research the epitalon half life at the same time. Epitalon and SS-31 are studied for entirely different purposes, so their pharmacokinetics are not interchangeable.
What Can Change How Long SS-31 Stays in the Body
Half-life is not a fixed property of a molecule. Several practical factors can stretch or shrink the time SS-31 spends in circulation.
- Route of administration: an IV infusion delivers the full dose at once, while a subcutaneous injection absorbs more slowly and can leave a small depot at the injection site.
- Injection site and technique: abdominal injections tend to absorb faster than thigh injections.
- Species differences: rodent half-lives run from minutes to a couple of hours, so animal doses do not translate directly to humans.
- Organ function: peptides are broken down by peptidases and cleared as metabolites, so kidney and liver function can alter exposure.
- Formulation and purity: home-reconstituted research material is not the same product as a sterile pharmacy-compounded solution.
Safety, Side Effects, and Legal Status
Elamipretide is not FDA-approved for human use in the United States, and regulators have declined its lead applications even after late-stage trials. Any SS-31 sold today is a research chemical, not a medicine.
Reported ss 31 side effects in clinical trials include injection-site reactions, headache, nausea, dizziness, and fatigue. Serious events were uncommon in published studies, but those trials were small and enrolled specific patient groups, so the safety profile for healthy users is largely undefined.
Anyone searching for where to buy ss-31 peptide should understand that research-grade vials are not tested for sterility, identity, or dose accuracy the way prescription products are. Independent testing is inconsistent, and mislabeled peptides are common in this market.
This article is for general information only and is not medical advice. Talk with a licensed healthcare professional before using any peptide, especially if you take prescription medication or have kidney, liver, or heart conditions.
The SS-31 half-life of about two hours explains the dosing patterns seen in research, but half-life alone does not tell you whether a peptide works or how to use it safely. Distribution, target binding, product quality, and the strength of human evidence matter just as much.
Frequently Asked Questions
How long does SS-31 stay in your system?
SS-31 (elamipretide) has a plasma half-life of roughly 1.5 to 2.5 hours, so about 90 percent of a dose clears the bloodstream within 10 hours. Effects may last longer than that because the peptide binds cardiolipin inside mitochondria, but tissue-level activity is difficult to measure directly in humans.
What is the typical SS-31 dosage used in studies?
The most common protocol in human trials is 40 mg injected subcutaneously once daily. Earlier intravenous studies used infusions of about 0.05 to 0.5 mg/kg per hour. There is no FDA-approved dose, because elamipretide has not been approved for any condition.
Is SS-31 FDA approved?
No. Elamipretide has not received FDA approval for human use, and the agency has issued complete response letters for its lead indications, including Barth syndrome. Products marketed online are sold as research chemicals and are not tested for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.